“Ascendis Health, a SA healthcare company valued at around R440m on the JSE, reported a small profit for the year ending in June 2024, showing signs of recovery after previous losses.” – News24 (4 Sept 2024).
However, the company is still facing liquidity challenges, partly due to a legal battle related to its recent delisting attempt. Ascendis’ revenue for the year fell by 4% to R1.47bn, but improved operating margins led to a marginal operating profit of R46.4m.
“The company in medical devices and consumer brands.The consumer brands segment includes p opular vitamin and supplement brands such as Solal, Bettaway, Vitaforce, and MenaCal.